Skip to main content
Clinical Trials/NL-OMON25401
NL-OMON25401RecruitingNot Applicable

A phase II study of sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) non-small lung cancer (NSCLC) with a K-Ras mutation.

Vrije Universiteit Medisch centrumPostbus 70571007 MB AmsterdamNetherlands0 sites46 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
46

Study Overview

Brief Summary

/A

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1. Histologically advanced NSCLC stage IIIB or IV harbouring a K-RAS mutation;
  • 2. Disease progression after at least 1 prior chemotherapy regimen that should include a platinum doublet;

Exclusion Criteria

  • Excluded medical conditions:
  • 1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arythmias requiring anti-arythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension;

Investigators

Sponsor
Vrije Universiteit Medisch centrumPostbus 70571007 MB AmsterdamNetherlands

Similar Trials